Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection

• Jingwei Bian,
• Rongsheng Zhao,
• Suodi Zhai,
• Zijian Li

Affiliations

Jingwei Bian

Department of Pharmacy, Peking University Third Hospital, Beijing, 100083, China; Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, 100083, China

Rongsheng Zhao

Department of Pharmacy, Peking University Third Hospital, Beijing 100083, China

Suodi Zhai

Department of Pharmacy, Peking University Third Hospital, Beijing 100083, China

Zijian Li

Corresponding author.; Department of Pharmacy, Peking University Third Hospital, Beijing 100083, China; Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, 100083, China